Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

High Expression of SMN circ4-2b-3 in SMA I Children Treated with Nusinersen is Associated with Improved Motor Outcomes

26 Nov 2024

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Congenital Anomalies and Fetal Surgery
Share to Neurogenetic and Muscular Disorders Research

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 39592557
DOI: 10.1007/s12035-024-04605-7

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

High Expression of SMN circ4-2b-3 in SMA I Children Treated with Nusinersen is Associated with Improved Motor OutcomesPMID 39592557Read ↗

Disease Modifying Therapies for the Management of Children with Spinal Muscular Atrophy (5q SMA): An Update on the Emerging Evidence.Semantic proximity Read ↗

Advances in Therapeutic Development for Spinal Muscular AtrophySemantic proximity Read ↗

Circulating MyomiRs as Potential Biomarkers to Monitor Response to Nusinersen in Pediatric SMA PatientsSemantic proximity Read ↗

Molecular Biomarkers for the Diagnosis, Prognosis, and Pharmacodynamics of Spinal Muscular AtrophySemantic proximity Read ↗

In Search of Spinal Muscular Atrophy Disease ModifiersSemantic proximity Read ↗

Spinal muscular atrophy: A changing phenotype beyond the clinical trials.Semantic proximity Read ↗

The Effects of Nusinersen Treatment on Respiratuar Status of Children with Spinal Muscular AtrophySemantic proximity Read ↗

Muscle microRNAs in the cerebrospinal fluid predict clinical response to nusinersen therapy in type II and type III spinal muscular atrophy patientsSemantic proximity Read ↗

Overview of Current Drugs and Molecules in Development for Spinal Muscular Atrophy TherapySemantic proximity Read ↗

Preliminary insights into RNA in CSF of pediatric SMA patients after 6 months of nusinersen.Semantic proximity Read ↗

Type I PRMT inhibitor MS023 promotes <i>SMN2</i> exon 7 inclusion and synergizes with nusinersen to rescue the phenotype of SMA miceSemantic proximity Read ↗

Nusinersen as a Therapeutic Agent for Spinal Muscular AtrophySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.